Charles Schwab Investment Management Inc. Sells 17,897 Shares of Alphatec Holdings, Inc. $ATEC

Key Points

• Charles Schwab Investment Management Inc. reduced its holdings in Alphatec Holdings, Inc. by 2.1%, selling 17,897 shares and holding a total of 828,327 shares valued at approximately $8.4 million.
• Alphatec reported Q2 earnings of $0.02 per share, exceeding analysts' expectations, alongside a revenue of $185.54 million, up 27.5% year-over-year.
• Several research firms have given Alphatec a buy rating, with Barclays raising its price target to $22 and a consensus target price of $18.50 among six analysts.

Charles Schwab Investment Management Inc. reduced its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 2.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 828,327 shares of the medical technology company's stock after selling 17,897 shares during the period. Charles Schwab Investment Management Inc. owned 0.57% of Alphatec worth $8,399,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Alphatec by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock worth $60,990,000 after buying an additional 45,792 shares during the period. Royal Bank of Canada lifted its holdings in shares of Alphatec by 171.2% during the 4th quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock worth $29,240,000 after acquiring an additional 2,010,806 shares during the period. Nuveen Asset Management LLC increased its position in Alphatec by 78.4% during the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock worth $23,730,000 after purchasing an additional 1,136,330 shares in the last quarter. Cerity Partners LLC increased its position in Alphatec by 1.6% during the 1st quarter. Cerity Partners LLC now owns 1,859,137 shares of the medical technology company's stock worth $18,852,000 after purchasing an additional 30,072 shares in the last quarter. Finally, Emerald Advisers LLC increased its position in Alphatec by 11.5% in the 1st quarter. Emerald Advisers LLC now owns 1,623,449 shares of the medical technology company's stock valued at $16,462,000 after acquiring an additional 167,416 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alphatec

In other news, General Counsel Tyson Eliot Marshall sold 18,092 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total value of $269,751.72. Following the transaction, the general counsel owned 438,331 shares in the company, valued at $6,535,515.21. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Craig E. Hunsaker sold 186,122 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $12.34, for a total transaction of $2,296,745.48. Following the sale, the executive vice president owned 1,463,896 shares in the company, valued at approximately $18,064,476.64. The trade was a 11.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 410,247 shares of company stock worth $5,376,804 in the last quarter. Company insiders own 22.80% of the company's stock.

Alphatec Stock Performance

Shares of Alphatec stock opened at $15.84 on Tuesday. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -14.02 and a beta of 1.05. The firm's 50-day moving average is $12.47 and its 200 day moving average is $11.60. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $16.47. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million for the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. Alphatec's revenue was up 27.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ATEC. Barclays reiterated an "overweight" rating and set a $22.00 price objective (up from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Friday, August 1st. Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Wall Street Zen upgraded shares of Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $18.50.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Want to see what other hedge funds are holding ATEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.